Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory T(11;14) Multiple Myeloma

British Journal of Haematology- United Kingdom

doi 10.1111/bjh.16454

Full Text

Abstract

Available in

Date

February 3, 2020

Authors

Diana Basali

Rajshekhar Chakraborty

Publisher

Wiley

Related search

Successful Venetoclax Salvage in the Setting of Refractory, Dialysis-Dependent Multiple Myeloma With T(11;14)

Haematologica

Hematology

2019

English

Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology

Oncology

2018

English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research

Medicine

2010

English

Systematic Review and Meta-Analysis of the Efficacy and Safety of Novel Monoclonal Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma

Oncotarget

Oncology

2017

English

MYEOV (Myeloma Overexpressed (In a Subset of T(11;14) Positive Multiple Myelomas))

Atlas of Genetics and Cytogenetics in Oncology and Haematology

English

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Hematological Oncology

English

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Hematological Oncology

English

Immortal Time Bias in Retrospective Analysis: Comment on ‘Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma’

English

Amanote Research

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory T(11;14) Multiple Myeloma

British Journal of Haematology- United Kingdom

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Successful Venetoclax Salvage in the Setting of Refractory, Dialysis-Dependent Multiple Myeloma With T(11;14)

Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Carfilzomib for Relapsed or Refractory Multiple Myeloma

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

Systematic Review and Meta-Analysis of the Efficacy and Safety of Novel Monoclonal Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma

MYEOV (Myeloma Overexpressed (In a Subset of T(11;14) Positive Multiple Myelomas))

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Immortal Time Bias in Retrospective Analysis: Comment on ‘Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma’